A Randomized, Double-Blind, to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.

Start Date27 Sep 2023

Sponsor / Collaborator

Alexza Pharmaceuticals, Inc.

[+3]

CTR20232033 / CompletedPhase 1

一项在中国健康受试者中评价单次给予盐酸阿扑吗啡注射液（皮下注射）的药代动力学特征、安全性、耐受性的I 期、开放性临床研究

[Translation] A Phase I, open-label clinical study to evaluate the pharmacokinetic characteristics, safety, and tolerability of a single dose of apomorphine hydrochloride injection (subcutaneous injection) in healthy Chinese subjects

主要目的：评估在中国健康受试者中单次给予盐酸阿扑吗啡注射液（皮下注射）1 mg、2 mg、3 mg 的药代动力学特征；次要目的：评估在中国健康受试者中单次给予盐酸阿扑吗啡注射液（皮下注射）1 mg、2 mg、3 mg 的安全性和耐受性。

[Translation]

Primary objective: To evaluate the pharmacokinetic characteristics of apomorphine hydrochloride injection (subcutaneous injection) of 1 mg, 2 mg, and 3 mg in healthy Chinese subjects; Secondary objective: To evaluate the safety and tolerability of apomorphine hydrochloride injection (subcutaneous injection) of 1 mg, 2 mg, and 3 mg in healthy Chinese subjects.

Start Date13 Jul 2023

Sponsor / Collaborator

Ignis Therapeutics (Suzhou) Limited

[+3]

NCT05529095 / Not yet recruitingPhase 4IIT

Open Label and Placebo-Controlled Assessment of Sublingual Apomorphine (Kynmobi) as Adjunct Therapy for Patients With Refractory Restless Legs Syndrome

This is an open label, short placebo-controlled trial in Restless Legs Syndrome (RLS) patients inadequately treated with standard therapy. Investigators hypothesize that the study drug, sublingual apomorphine (Kynmobi), may improve RLS breakthrough symptoms. This study is designed to determine if sublingual apomorphine improves breakthrough symptoms in RLS patients, in addition to subjective responses.

Start Date01 Sep 2022

Sponsor / Collaborator

The Methodist Hospital Research Institute

[+1]

100 Clinical Results associated with Apomorphine Hydrochloride

100 Translational Medicine associated with Apomorphine Hydrochloride

100 Patents (Medical) associated with Apomorphine Hydrochloride

199

Literatures (Medical) associated with Apomorphine Hydrochloride

01 May 2024·Clinical and Translational Science

Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients

Article

Author: Tuk, Bert ; Merkus, Frans ; Thijssen, Eva ; Cakici, Michel ; van Velze, Veerle ; Kremer, Philip ; Klaassen, Erica ; van Laar, Teus ; Groeneveld, Geert Jan

AbstractApomorphine, used to treat OFF episodes in patients with Parkinson's disease (PD), is typically administered via subcutaneous injections. Administration of an oromucosal solution could offer a non‐invasive and user‐friendly alternative. This two‐part clinical study evaluated the safety, tolerability, pharmacokinetics (PK), and dose proportionality of a novel apomorphine hydrochloride oromucosal solution, as well as its relative bioavailability to subcutaneous apomorphine injection and apomorphine sublingual film. In part A of the study, 12 patients with PD received 2 mg oromucosal apomorphine (4% weight/volume) and 2 mg subcutaneous apomorphine in a randomized order, followed by 4 and 8 mg oromucosal apomorphine. In part B of the study, 13 patients with PD received 7 mg oromucosal apomorphine (7% weight/volume) and 30 mg sublingual apomorphine in a randomized order, followed by 14 mg oromucosal apomorphine. Washout between dose administrations in both study parts was at least 2 days. Safety, tolerability, and PK were assessed pre‐ and post‐dose. Both study parts showed that oromucosal apomorphine was generally well‐tolerated. Observed side effects were typical for apomorphine administration and included asymptomatic orthostatic hypotension, yawning, fatigue, and somnolence. Oromucosal apomorphine exposure increased with dose, although less than dose proportional. The mean (SD) maximum exposure reached with 14 mg oromucosal apomorphine was 753.0 (298.6) ng*min/mL (area under the plasma concentration–time curve from zero to infinity) and 8.0 (3.3) ng/mL (maximum plasma concentration). This was comparable to exposure reached after 2 mg subcutaneous apomorphine and approximately half of the exposure observed with 30 mg sublingual apomorphine. In summary, clinically relevant plasma concentrations could be reached in PD patients without tolerability issues.

01 Feb 2024·International Journal of Neuroscience

Efficacy and safety of apomorphine pump infusion in Filipino patients insufficiently controlled on oral anti-Parkinson medications: an open-label, pilot study

Article

Author: Ostrea, Marc C. ; Rosales, Raymond L. ; Joya-Tanglao, Michelle

BACKGROUNDApomorphine hydrochloride is used in the management of advanced Parkinson disease (PD), either as a rescue medication for off periods during levodopa therapy or as a maintenance pump medication. This is the first study to describe the effects of apomorphine in Filipino patients with PD.OBJECTIVETo evaluate the safety and efficacy of apomorphine ampules (APO-go®) pump infusion in the treatment of motor fluctuations in patients inadequately controlled on oral anti-Parkinson medications.METHODSPatients diagnosed with PD who developed motor fluctuations with levodopa were evaluated at baseline and at the end of the study using the Modified Hoehn and Yahr (H&Y) Scale, the Unified Parkinson's Disease Rating Scale (UPDRS) and the Abnormal Involuntary Movement Scale (AIMS). After initial assessment, patients were administered 20 ampules of apomorphine hydrochloride 10 mg/mL by infusion pump over 20 days. Intention-to-treat (ITT) analysis included all patients who completed at least one posttreatment assessment. Motor disability based on modified H&Y scores, motor function and complications of therapy pre- and posttreatment were compared using Wilcoxon Signed Rank test. Chi-squared test was used to compare outcomes by age and sex. Frequencies of adverse reactions were recorded to evaluate the tolerability of the medication.RESULTSTen patients (mean age 63 ± 9.7 years), 3 male and 7 female, were enrolled in the study. Patients were given apomorphine for at most 16 days. The doses used were 2.5 mg/0.50 mL (n = 2), 3 mg/0.60 mL (n = 6), 4 mg/0.80 mL (n = 1) and 7 mg/1.40 mL (n = 1). After obtaining the threshold dose, two patients discontinued treatment. Eight of nine patients showed significant improvement in H&Y scores after treatment (p < 0.017). There was marked improvement after 10 days of treatment in at least five of 10 patients in terms of motor function using UPDRS, which included tremor (p < 0.034), rigidity (p < 0.002), facial expression (p < 0.014), finger taps (p < 0.008), foot taps (p < 0.014) and gait (p < 0.006). Significant changes from pre- to posttreatment scores in the frequency of dyskinesias (p < 0.010) and dystonia (p < 0.025) were observed. Nine focus areas of AIMS showed significant improvements in the muscles of facial expression (p < 0.020), upper (p < 0.016) and lower extremities (p < 0.010), incapacitation by abnormal movement (p < 0.010) and patients' awareness of abnormal movements (p < 0.039). Six patients experienced adverse events, none of which were related to the study drug.CONCLUSIONApomorphine hydrochloride pump infusion therapy is potentially effective and safe in the treatment of motor fluctuations in Filipino patients with PD. This pilot study springboards safe engagements of Filipino PD patients in multicenter, large-scale trials.

01 Jan 2024·Pharmaceutical Research

Fabrication and Characterization of Dissolving Microneedles for Transdermal Drug Delivery of Apomorphine Hydrochloride in Parkinson’s Disease

Article

Author: Sakaue, Motoharu ; Yamamoto, Eiichi ; Ozawa, Aisa ; Ando, Daisuke ; Koide, Tatsuo ; Sato, Yoji ; Izutsu, Ken-Ichi ; Miyazaki, Tamaki

PURPOSEWe fabricated and characterized polyvinyl alcohol (PVA)-based dissolving microneedles (MNs) for transdermal drug delivery of apomorphine hydrochloride (APO), which is used in treating the wearing-off phenomenon observed in Parkinson's disease.METHODSWe fabricated MN arrays with 11 × 11 needles of four different lengths (300, 600, 900, and 1200 μm) by micromolding. The APO-loaded dissolving MNs were characterized in terms of their physicochemical and functional properties. We also compared the pharmacokinetic parameters after drug administration using MNs with those after subcutaneous injection by analyzing the blood concentration of APO in rats.RESULTSPVA-based dissolving MNs longer than 600 μm could effectively puncture the stratum corneum of the rat skin with penetrability of approximately one-third of the needle length. Although APO is known to have chemical stability issues in aqueous solutions, the drug content in APO-loaded MNs was retained at 25°C for 12 weeks. The concentration of APO after the administration of APO-loaded 600-μm MNs that dissolved completely in skin within 60 min was 81%. The absorption of 200-μg APO delivered by MNs showed a T_max of 20 min, C_max of 76 ng/mL, and AUC_{0-120 min} of 2,829 ng・min/mL, compared with a T_max of 5 min, C_max of 126 ng/mL, and AUC_{0-120 min} of 3,224 ng・min/mL for subcutaneous injection. The bioavailability in terms of AUC_{0-120 min} of APO delivered by MNs was 88%.CONCLUSIONAPO-loaded dissolving MNs can deliver APO via skin into the systemic circulation with rapid absorption and high bioavailability.

News (Medical) associated with Apomorphine Hydrochloride

28 Oct 2024

·www.globenewswire.com

ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS

AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that pancreatic cancer patients with high expression levels of either TGFB2, IRF9, or IFI27 showed improvement of median overall survival from 16-20 months to 72 months for patients with low levels of expression for both TGFB2 and either IRF9 or IFI27 validating that knockdown of IRF9 and IFI27 as therapeutic targets for TGFB2 therapeutics. https://www.mdpi.com/3003472 The publications of this series are available at Pubmed as follow: 1) TGFB2 mRNA Levels Prognostically Interact with Interferon-Alpha Receptor Activation of IRF9 and IFI27, and an Immune Checkpoint LGALS9 to Impact Overall Survival in Pancreatic Ductal Adenocarcinoma. Qazi S, Trieu V. Int J Mol Sci. 2024 Oct 18;25(20):11221. doi: 10.3390/ijms252011221. PMID: 39457004 2) Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas. Trieu V, Maida AE, Qazi S. Cancers (Basel). 2024 Mar 19;16(6):1202. doi: 10.3390/cancers16061202. PMID: 38539537 Free PMC article. 3) Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients. Qazi S, Talebi Z, Trieu V. Biomedicines. 2024 Jan 15;12(1):191. doi: 10.3390/biomedicines12010191. PMID: 38255296 Free PMC article. 4) High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma. Uckun FM, Qazi S, Trieu V. Cancers (Basel). 2023 Mar 9;15(6):1676. doi: 10.3390/cancers15061676. PMID: 36980562 Free PMC article. Additional information on our current phase 3 can be found at: https://www.youtube.com/watch?v=5KqdbySDRKE About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

AcquisitionPhase 3

23 Oct 2024

·www.globenewswire.com

ONCOTELIC PRESENTATION AT PRECISION IN DRUG DISCOVERY & PRECLINICAL SUMMIT SAN DIEGO 2024

AGOURA HILLS, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Precision in Drug Discovery & Preclinical Summit. Dr. Wen-Han Chang, Nanomedicine Sr. Manager, and Dr. Tara Zand, Research Scientist, presented Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://events.precision-globe.com/single-event/precision-drug-discovery-preclinical-summit-san-diego##. Dr. Chang and Dr. Zand are experienced nanomedicine and precision drug development dedicated to finding the cure for pancreatic and brain cancers. https://www.linkedin.com/in/wen-han-chang-106002139/ https://www.linkedin.com/in/tara-zand-phd-512042b5/ https://www.linkedin.com/posts/precision-evolution-global-inc_pddpsummit-sandiego-precisionevolutionglobal-activity-7253106596543619072-IqP5/ About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

Acquisition

20 Aug 2024

·www.globenewswire.com

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Aug. 19, 2024 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease (PD). The resubmission is now considered filed, with a user fee goal date (PDUFA date) of February 1, 2025. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. The content above comes from the network. if any infringement, please contact us to modify.

NDA

100 Deals associated with Apomorphine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02004	Apomorphine Hydrochloride	G04BE07 N04BC07	DB00714

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Parkinson Disease	US	MDD US Operations, LLC	20 Apr 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parkinson Disease	Discovery	US	Sumitomo Pharma America, Inc.	21 May 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02542696 (Phase 3 study, CTgov)	Phase 3	Motor Disorders \| Parkinson Disease	496	APL-130277	gqtnttecmo(xzovzchukf) = wlixjizdxe uglwuqwhix (ihfhrhiung, szgvqxptlv - jjuiyhzutd) View more	-	22 Nov 2023
MDS2023	Not Applicable	-	-	apomorphine sublingual film	(ojijbslhfr) = uergstgwty qaqtqfucaj (gibavdkdtk ) View more	-	27 Aug 2023
MDS2023	Not Applicable	-	-	apomorphine sublingual film	(ojijbslhfr) = mtklocohtt qaqtqfucaj (gibavdkdtk ) View more	-	27 Aug 2023
MDS2022	Not Applicable	Drug-Related Side Effects and Adverse Reactions	9,934	Apomorphine	lysfrsxacr(wcyyodfera) = msbwdluaoi gwwqqsbgwd (qojjwekpbs ) View more	-	15 Sep 2022
NCT02940912 (APOMORPHEE, Pubmed) Manual	Phase 4	Sleep Initiation and Maintenance Disorders \| Parkinson Disease First line	46	apomorphine	duyhefsusa(anjhizxmzr) = zximxarhfw hhxbrdctub (qdasbozzdk ) View more	Positive	01 May 2022
NCT02940912 (APOMORPHEE, Pubmed) Manual	Phase 4		46	Placebo	duyhefsusa(anjhizxmzr) = euinutjmyx hhxbrdctub (qdasbozzdk ) View more	Positive	01 May 2022
NCT02469090 (not available, MDS2021)	Phase 3	Motor Disorders \| Parkinson Disease	141	Apomorphine Sublingual Film	sgdfamyhem(fgbrtgylho) = Acute episodes of nausea varied by dose, occurring in 10/141 (7%) patients with 10 mg APL, 6/123 (5%) with 15 mg, 5/88 (6%) with 20 mg, 3/57 (5%) with 25 mg, 4/36 (11%) with 30 mg, and 2/20 (10%) with 35 mg. Most acute episodes of nausea were mild (57%), with 30% classified as moderate and 13% as severe. Vomiting occurred in 2 patients who experienced severe nausea and 1 patient who experienced moderate nausea. qvkrrdbemu (wvmvmwmtjd )	Positive	17 Sep 2021
NCT02542696 (Phase 3 study, MDS2021)	Phase 3	Parkinson Disease	-	Apomorphine Sublingual Film	(jpwjhzcxcp) = deczonakgb wkyloilaod (vowuhyzaim ) View more	Positive	17 Sep 2021
NCT02542696 (Phase 3 study, MDS2021)	Phase 3	Parkinson Disease	-	Apomorphine Sublingual Film	(jpwjhzcxcp) = jmyqmplbil wkyloilaod (vowuhyzaim ) View more	Positive	17 Sep 2021
NCT02542696 (Phase 3 study, MDS2021)	Phase 3	Parkinson Disease	397	Apomorphine Sublingual Film	(dnuzznpntl) = drauymcjtz iawhowgtca (yqtddpqjrn ) View more	Positive	17 Sep 2021
NCT02542696 (MDS2021)	Phase 3	Parkinson Disease	176	Apomorphine Sublingual Film	(rreowjvset) = ceycgyoyrj ohzqproxkj (micdrlvzme ) View more	-	17 Sep 2021
NCT02006121 (TOLEDO, Pubmed)	Phase 3	Parkinson Disease Maintenance	107	Apomorphine infusion	(jgnhmtfqxx) = fatigue obguipdpxl (gglpykyjdx ) View more	-	12 Jan 2021
PC and LTS study (MDS2020)	Not Applicable	Parkinson Disease	425	Apomorphine sublingual film	qzkgjyiusg(skcxnowmvw) = TEAEs of dyskinesia were not reported in the PC study and occurred in 7% (28/425) of patients in the LTS study, with no apparent dose relationship. jlhbdtqizs (wqfpwmduxm )	Positive	12 Sep 2020
PC and LTS study (MDS2020)	Not Applicable	Parkinson Disease	425	Placebo		Positive	12 Sep 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis